This article is adapted from STAT’s latest report, “2023 Update: ranking biotech’s top venture capital firms.”
Right now, venture capital firms are struggling with the impact of a persistently anemic biotech market. But if past downturns are any indication, some VCs will steer out of the slump into brighter times.
The story of one fund overseen by The Column Group, a firm profiled in the 2023 edition of “Ranking biotech’s top venture capital firms,” STAT’s annual report on VC performance, shows how that might happen.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect